^
    Back
    Association details:
    Biomarker:BRIP1 mutation
    Cancer:Prostate Cancer
    Drug:Rubraca (rucaparib) (PARP inhibitor)
    Direction:Sensitive
    Evidence:
    Evidence Level:
    Sensitive: C2 – Inclusion Criteria
    Source:
    clinicaltrials.gov
    Title:

    A Study to Evaluate Rucaparib in Participants With Solid Tumors and With Deleterious Mutations in HRR Genes

    Excerpt:
    ...- Have a deleterious mutation (germline or somatic) in BRCA1, BRCA2, PALB2, RAD51C, RAD51D, BARD1, BRIP1, FANCA, NBN, RAD51 or RAD51B....
    Trial ID:
    LODESTAR
    Evidence Level:
    Sensitive: C3 – Early Trials
    Source:
    ESMO 2018
    Title:

    Preliminary Results from TRITON2: A Phase 2 Study of Rucaparib in Patients with Metastatic Castration-Resistant Prostate Cancer (mCRPC) Associated with Homologous Recombination Repair (HRR) Gene Alterations

    Published date:
    10/19/2019
    Excerpt:
    A confirmed objective response by investigator assessment was also observed in 1 patient with a BRIP1 alteration and 1 patient with a FANCA alteration (Table 2)
    Trial ID:
    TRITON2; 2016-003162-13